New Drug Holds Promise for Combating Alzheimer's

Join Our Community of Science Lovers!

On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.

A key feature of a number of diseases¿most noticeably Alzheimer's¿is the presence of so-called amyloid deposits comprised of insoluble clumps of proteins that kill surrounding cells. A naturally occurring protein present in the bloodstream known as serum amyloid P component (SAP) aids these plaques in destroying healthy tissue by binding to the amyloid fibers and preventing the body from breaking them down. Findings published today in the journal Nature suggest that a drug designed to thwart the action of SAP holds promise for treating human amyloid diseases.

Mark Pepys of the Royal Free and University College Medical School in London and his colleagues targeted SAP with a new drug called CPHPC. The molecule blocks the binding of SAP to amyloid fibers and instead causes SAP molecules to bind to one another. These SAP protein packs are then removed from the bloodstream and metabolized by the liver. In mice, administering the drug removed SAP from plaques and led to a gradual reduction in the size of the deposits. The researchers also tested CPHPC on 19 patients suffering from systemic amyloidosis, a disease in which protein clumps form throughout the body. They found that SAP levels in the blood were reduced without adverse side effects. According to the report, continued treatment with CPHPC is most likely required to completely clear SAP from major amyloid deposits and maximize the reduction in the plaques.

Exactly what the results will mean for treatment of Alzheimer's disease so far remains unclear. Says Pepys, "Although amyloid deposits are closely related with Alzheimer's disease and maturity onset diabetes, it is not known whether they actually cause these diseases." Whether CPHPC can combat the memory-robbing disease is the focus of clinical trials set to start this year.

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American